company background image
MOR2 logo

MorphoSys DB:MOR2 Stock Report

Last Price

€16.30

Market Cap

€2.5b

7D

-2.4%

1Y

148.9%

Updated

06 Aug, 2024

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MOR2 Stock Overview

Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. More details

MOR2 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

MorphoSys AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for MorphoSys
Historical stock prices
Current Share Price€16.30
52 Week High€17.50
52 Week Low€3.56
Beta0.66
1 Month Change-0.61%
3 Month Change0.62%
1 Year Change148.86%
3 Year Change40.52%
5 Year Change-39.63%
Change since IPO-19.74%

Recent News & Updates

Recent updates

Shareholder Returns

MOR2DE BiotechsDE Market
7D-2.4%1.0%1.7%
1Y148.9%-6.8%12.9%

Return vs Industry: MOR2 exceeded the German Biotechs industry which returned -27.4% over the past year.

Return vs Market: MOR2 exceeded the German Market which returned -3.1% over the past year.

Price Volatility

Is MOR2's price volatile compared to industry and market?
MOR2 volatility
MOR2 Average Weekly Movement4.2%
Biotechs Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: MOR2 has not had significant price volatility in the past 3 months.

Volatility Over Time: MOR2's weekly volatility has decreased from 14% to 4% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992464Arkadius Pichotawww.morphosys.com

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.

MorphoSys AG Fundamentals Summary

How do MorphoSys's earnings and revenue compare to its market cap?
MOR2 fundamental statistics
Market cap€2.53b
Earnings (TTM)-€468.57m
Revenue (TTM)€241.47m

10.5x

P/S Ratio

-5.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MOR2 income statement (TTM)
Revenue€241.47m
Cost of Revenue€60.14m
Gross Profit€181.33m
Other Expenses€649.90m
Earnings-€468.57m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 07, 2024

Earnings per share (EPS)-12.44
Gross Margin75.09%
Net Profit Margin-194.05%
Debt/Equity Ratio-658.0%

How did MOR2 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/06 02:45
End of Day Share Price 2024/08/06 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MorphoSys AG is covered by 34 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olav ZilianBaader Helvea Equity Research
Brian BalchinBarclays
Rosie TurnerBarclays